|
|
Post by mnholdem on Oct 20, 2017 7:04:09 GMT -5
From the Overview section within the Prospectus Supplement Summary (pg S-3):
During the second half of 2016, we utilized a contract sales organization to promote Afrezza while we focused our internal resources on establishing a channel strategy, entering into distribution agreements and developing co-pay assistance programs, a voucher program, data agreements and payor relationships. In early 2017, we recruited our own specialty sales force to promote Afrezza to endocrinologists and certain high-prescribing primary care physicians. In the future, we may seek to supplement our sales force through a co-promotion arrangement — an agreement with a third party that has an underutilized primary care sales force, which can be used to promote Afrezza to greater number of primary care physicians [emphasis added].
Source: www.sec.gov/Archives/edgar/data/899460/000119312517307995/d473688d424b5.htm
---
The shift from endocrinologists to PCPs was expected, but could "co-promotion arrangement" be part of what the MannKind-OneDrop Collaboration entails?
 |
|
|
|
Post by reality on Oct 20, 2017 7:15:31 GMT -5
Let's hope so!
|
|
|
|
Post by agedhippie on Oct 20, 2017 7:15:55 GMT -5
From the Overview section within the Prospectus Supplement Summary (pg S-3):
During the second half of 2016, we utilized a contract sales organization to promote Afrezza while we focused our internal resources on establishing a channel strategy, entering into distribution agreements and developing co-pay assistance programs, a voucher program, data agreements and payor relationships. In early 2017, we recruited our own specialty sales force to promote Afrezza to endocrinologists and certain high-prescribing primary care physicians. In the future, we may seek to supplement our sales force through a co-promotion arrangement — an agreement with a third party that has an underutilized primary care sales force, which can be used to promote Afrezza to greater number of primary care physicians [emphasis added].
Source: www.sec.gov/Archives/edgar/data/899460/000119312517307995/d473688d424b5.htm
---
The shift from endocrinologists to PCPs was expected, but could "co-promotion arrangement" be part of what the MannKind-OneDrop Collaboration entails?
Unless we were doing the selling that would require One Drop to change their current sales model which is online and DTC. That's not to say that One Drop will not change the way they sell, just that they don't sell that way today. |
|
|
|
Post by madog365 on Oct 20, 2017 8:09:03 GMT -5
From the Overview section within the Prospectus Supplement Summary (pg S-3):
During the second half of 2016, we utilized a contract sales organization to promote Afrezza while we focused our internal resources on establishing a channel strategy, entering into distribution agreements and developing co-pay assistance programs, a voucher program, data agreements and payor relationships. In early 2017, we recruited our own specialty sales force to promote Afrezza to endocrinologists and certain high-prescribing primary care physicians. In the future, we may seek to supplement our sales force through a co-promotion arrangement — an agreement with a third party that has an underutilized primary care sales force, which can be used to promote Afrezza to greater number of primary care physicians [emphasis added].
Source: www.sec.gov/Archives/edgar/data/899460/000119312517307995/d473688d424b5.htm
---
The shift from endocrinologists to PCPs was expected, but could "co-promotion arrangement" be part of what the MannKind-OneDrop Collaboration entails?
This doesn't read like it would be one drop to me. Does one drop even have a primary care salesforce (thought they focused on DTC sales online) and if they do, it's definitely small and not underutilized. |
|
|
|
Post by jlaw277 on Oct 20, 2017 8:18:10 GMT -5
Mike mentioned this idea in the Q&A of the last quarterly conference call. If you look up similar agreements you find that it looks more like a traditional partnership than what they might have with One Drop. Could be fairly significant if they teamed with a good name.
Here's an example:
“This collaboration enables Ironwood and Allergan to work together to bring forward two innovative medicines demonstrated to improve the abdominal pain and bowel dysfunction that define IBS-C and IBS-D, two types of IBS that impact nearly 30 million adult Americans,” said Bill Meury, executive vice president of commercial, North American brands for Allergan. “Allergan and Ironwood have an established and successful partnership co-promoting LINZESS in the U.S. market, and we have demonstrated the strength of our combined commercial teams in accessing and educating both gastroenterologists and primary care physicians.”
“The VIBERZI co-promotion agreement is a natural extension of Ironwood’s focus on bringing innovative solutions to patients suffering from functional gastrointestinal disorders, and particularly disorders characterized by abdominal pain,” said Tom McCourt, chief commercial officer of Ironwood. “We believe our promotion of VIBERZI will drive value for Ironwood and reinforce our market leadership position in this category. The co-promote requires no additional Ironwood investment and is synergistic with our existing commercial efforts for LINZESS and Cologuard®, further strengthening our commercial capabilities as we prepare to market additional gastrointestinal and primary care products.”
|
|
|
|
Post by itellthefuture777 on Oct 20, 2017 9:19:43 GMT -5
From the Overview section within the Prospectus Supplement Summary (pg S-3):
During the second half of 2016, we utilized a contract sales organization to promote Afrezza while we focused our internal resources on establishing a channel strategy, entering into distribution agreements and developing co-pay assistance programs, a voucher program, data agreements and payor relationships. In early 2017, we recruited our own specialty sales force to promote Afrezza to endocrinologists and certain high-prescribing primary care physicians. In the future, we may seek to supplement our sales force through a co-promotion arrangement — an agreement with a third party that has an underutilized primary care sales force, which can be used to promote Afrezza to greater number of primary care physicians [emphasis added].
Source: www.sec.gov/Archives/edgar/data/899460/000119312517307995/d473688d424b5.htm
---
The shift from endocrinologists to PCPs was expected, but could "co-promotion arrangement" be part of what the MannKind-OneDrop Collaboration entails?
www.fiercepharma.com/pharma/citing-ebb-and-flow-pharma-merck-says-it-s-cutting-1-800-sales-staffers
|
|
|
|
Post by itellthefuture777 on Oct 20, 2017 9:22:45 GMT -5
Looks like it's Merck imo!
|
|
|
|
Post by cjm18 on Oct 20, 2017 9:32:02 GMT -5
So what's a common example? We sell their products and they sell afrezza?
|
|
|
|
Post by straightly on Oct 20, 2017 9:33:36 GMT -5
Looks like it's Merck imo! Things are definitely a changing. Ours is an changing agent straightly. Only a chance, but the latest events have made ours a feasible one. How much does this chance worth? Somebody believe it to be > $6 and put up $60m + $1m to it. We the drama watchers will have our entertainments nonetheless. |
|
|
|
Post by madog365 on Oct 20, 2017 9:37:36 GMT -5
So what's a common example? We sell their products and they sell afrezza? Typically co-promotions involve complimentary non-competitive products. Somebody like an Abbott Labs would make sense - since they will be promoting the recently approved Libre soon and don't have an insulin product on the market. They are also global and operate in the regional markets listed in the MNKD presentation. And Mike did tweet them congratulations recently |
|
|
|
Post by itellthefuture777 on Oct 20, 2017 9:44:12 GMT -5
So what's a common example? We sell their products and they sell afrezza? A deal could be simular to Sanofi but 7x the 1 billion buy in price to get the 35% of co-promotion if it was the same size sales forces as Sanofi's..probably a much larger effort is my guess. Mnkd does what Sanofi did with 1/7th the staff..to use as a pricing scale...So the valuation of Afrezza also went way way up with the new label since then..so $7 billion up front for 35% of Afrezza..that should motivate them to sale a lot more then giving them 65% like Sanofi got so it could sit on its ass while MNKD scrapped by...no more of that.. |
|
|
|
Post by boca1girl on Oct 20, 2017 11:17:05 GMT -5
So what's a common example? We sell their products and they sell afrezza? Typically co-promotions involve complimentary non-competitive products. Somebody like an Abbott Labs would make sense - since they will be promoting the recently approved Libre soon and don't have an insulin product on the market. They are also global and operate in the regional markets listed in the MNKD presentation. And Mike did tweet them congratulations recently This example of co-promotion makes sense but would there be any revenue sharing? If MNKD keeps all the Afrezza revenue, teriffic. I would hope we wouldn’t have to share costs except for maybe joint advertising Libre/Afrezza. I would doubt there would be any up front $$ associated with this type of agreement since both would benefit from expected increased sales. |
|
|
|
Post by madog365 on Oct 20, 2017 11:45:37 GMT -5
A deal could really be structured in many ways , but i would assume if they are selling Afrezza (and taking on the costs of sales) then they will be sharing some percentage of revenue from those sales. A co-promotion honestly makes a lot of sense because Afrezza is the insulin that will make their devices look the best with its fast action and that applies vice versa making Afrezza look better with a CGM. Now the ex-us sales is where it get's more interesting. Outside of the US they can take on a distribution agreement similar to what Sanofi previously did in the US with an upfront payment and milestones. Mannkind manufactures the product and they sell it, simple. Abbott's CGM system is already approved in 42 countries and they are also targeting the UAE market as far as i can tell. Looks like they are actually presenting at the USA Healthcare Symposium in Dubai focused on Diabetes in the UAE. Interesting agenda with a few familiar names in Daman (partnered with OneDrop). www.kallman.com/usahs-2017-agenda |
|
|
|
Post by sportsrancho on Oct 20, 2017 11:50:30 GMT -5
So what's a common example? We sell their products and they sell afrezza? Typically co-promotions involve complimentary non-competitive products. Somebody like an Abbott Labs would make sense - since they will be promoting the recently approved Libre soon and don't have an insulin product on the market. They are also global and operate in the regional markets listed in the MNKD presentation. And Mike did tweet them congratulations recently Makes a lot of sense to me:-) |
|
|
|
Post by radgray68 on Oct 20, 2017 13:41:51 GMT -5
Any of the glucose monitor companies could co-promote for us/with us. "Buy a glucose monitor, get a month's supply of needle-free Afrezza"
|
|
